- noodls•3 months ago
NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer
Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases WOBURN, Mass.--Sirtex Medical Limited (ASX: SRX) today announced ...
- noodls•4 months ago
ELPA Calls on Patients with Primary Liver Cancer (HCC) to Share their Experiences in First Global Survey
Results will provide doctors and cancer researchers with insights to improve liver cancer treatment now, and in the future ELPA has recently joined a special partnership with similar organisations across ...
- noodls•5 months ago
New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Sydney, Australia (11 October 2016) Sirtex Medical Limited (ASX:SRX) announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90) microspheres ...
SRX.AX: Summary for SIRTEX MED FPO - Yahoo Finance
Sirtex Medical Limited (SRX.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
|Day's range||17.39 - 17.80|
|52-week range||12.20 - 35.04|
|PE ratio (TTM)||20.85|
|Dividend & yield||0.31 (2.28%)|
|1y target est||N/A|